Reducing complexity in International Bladder Cancer Group intermediate‐risk non‐muscle‐invasive bladder cancer stratification: a three‐factor approach
Open Access
- 2 April 2026
- journal article
- Published by Wiley in BJU International
- Vol. 138 (2) , 244-249
Abstract
Objectives: To evaluate whether a simplified risk model preserves the prognostic performance of the International Bladder Cancer Group (IBCG) five‐factor risk stratification model in intermediate‐risk (IR) non‐muscle‐invasive bladder cancer (NMIBC). Patients and Methods: We performed a multicentre retrospective analysis of 2822 patients with IR NMIBC treated with transurethral resection of bladder tumour and intravesical therapy between 2005 and 2025. Multivariable Cox regression identified independent predictors of recurrence and progression. A simplified risk model was constructed using significant variables and compared with the full IBCG model using recurrence and progression rates, area under the curve analysis, and likelihood ratio testing. Results: A total of 2822 patients with IR NMIBC were included. When classified using the full IBCG model, 1143 (41%) were in the IR‐low, 1535 (54%) IR‐intermediate, and 144 (5%) IR‐high‐risk groups. On multivariable analysis, only multifocality, early recurrence, and failure of intravesical therapy independently predicted oncological outcomes. Using these factors, patients were stratified as IR‐low (no factors), IR‐intermediate (one factor), or IR‐high (two or more factors). Under the simplified model, 1535 (54%) patients were classified as IR‐low, 906 (32%) as IR‐intermediate, and 381 (14%) as IR‐high. The 3‐year recurrence and progression rates increased stepwise across simplified risk groups. Discriminative performance of the simplified model was comparable to the full model across all metrics, with no meaningful loss of discrimination. Conclusion: Three variables captured the most prognostic signal in this cohort without loss of discrimination compared with the full model. This simplified model is an internally validated refinement, with planned external validation to confirm generalisability and to ensure that simplified thresholds do not alter the clinically important IR‐high subgroup used in care and trials.Keywords
This publication has 8 references indexed in Scilit:
- Computational Histology Artificial Intelligence (CHAI) Enhances Risk Stratification of High-grade Ta Non–muscle-invasive Bladder Cancer in a Multicenter Cohort: Comparison to Current European Association of Urology and American Urological Association Stratification SchemesEuropean Urology, 2025
- Clinical Validation of the Intermediate-risk Non–muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group CollaborationEuropean Urology Oncology, 2024
- Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer GroupJournal of Clinical Oncology, 2023
- Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needsFrontiers in Oncology, 2023
- Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer GroupEuropean Urology Oncology, 2022
- Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO GuidelineJournal of Urology, 2016
- Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder CancerJournal of Urology, 2014
- Prognostic Significance of the 2004 WHO/ISUP Classification for Prediction of Recurrence, Progression, and Cancer-Specific Mortality of Non–Muscle-Invasive Urothelial Tumors of the Urinary BladderAmerican Journal of Clinical Pathology, 2010